Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026)
Bausch Health Companies' (BHC) quarterly Income from Non-Controlling Interests came in at -$8.0 million in Q1 2026, up 71.43% year-on-year from -$4.7 million in Q1 2025, and down 188.89% quarter-over-quarter from $9.0 million in Q4 2025.
Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Income from Non-Controlling Interests across 14 years of filings, most recently posting -$8.0 million for Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at -$8.0 million, up 71.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.0 million (up 58.54% YoY), and the FY2025 annual result was -$37.0 million, down 42.31% from the prior year.
- Income from Non-Controlling Interests came in at -$8.0 million for Q1 2026 at Bausch Health Companies, down from $9.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $9.0 million in Q4 2025 to a low of -$28.0 million in Q1 2025.
- The 5-year median for Income from Non-Controlling Interests is -$5.5 million (2023), against an average of -$4.8 million.
- Across the five-year window, Income from Non-Controlling Interests surged 200.0% in 2022 and slumped 1200.0% in 2024, its largest moves.
- Bausch Health Companies' Income from Non-Controlling Interests stood at $4.0 million in 2022, then slumped by 300.0% to -$8.0 million in 2023, then surged by 162.5% to $5.0 million in 2024, then jumped by 80.0% to $9.0 million in 2025, then slumped by 188.89% to -$8.0 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$8.0 million (Q1 2026), $9.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Bausch Health Companies | 1.91 Bn | 1.58 Bn | 2.48 Bn | -8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -20.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | -7.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -13.00 Mn |
| Dec 31, 2023 | -8.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Mar 31, 2021 | 3.00 Mn |